Key takeaways:

GLP-1 receptor agonists reduced mortality vs. DDP-4 inhibitors among older adults with cancer and type 2 diabetes.

More patient-clinician communication about GLP-1 therapy risks and benefits is needed.

Choice of therapy to control high blood sugar may affect survival among older adults with cancer and type 2 diabetes, according to study results.

Those who used GLP-1 receptor agonists exhibited significantly lower risk for all-cause mortality than those treated with dipeptidyl peptidase-4 (DPP-4) inhibitors. Results showed comparable mortality risks between users of GLP-1 agents and sodium-glucose transport protein 2 (SGLT2) inhibitors.

Data derived from Radwan RM, et al. JAMA Netw Open . 2025;doi:10.1001/jamanetworkopen.2025.21887.

The data — which support findin

See Full Page